LONDON and BOSTON, October 31, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that members of its senior management team will be presenting at the following biotech industry events over the coming weeks.
BIO-Europe 2013 (Vienna, Austria, 4-6 November)
Barry Kenny, Heptares' Chief Business Officer will present an overview of the Company at 11:15am, Wednesday, 6 November, in Room Schubert 1 (Level 1). Heptares' Chief Executive Officer, Malcolm Weir, will also be present at the event.
Boston Biotech Conference New York CEO Meeting (New York City, NY, USA, 12-13 November)
Malcolm Weir will participate in a panel discussion entitled "The Hot IPO Window: Impact on Private Financing Deals" at 11:10am on 12 November; and Dan Grau, Heptares' President, will chair a panel entitled "How is Personalized Medicine Guiding Drug Development in 2013?" at 8:45am on 13 November.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, schizophrenia, diabetes, attention disorders and chronic migraine. Our pharmaceutical partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
The HEPTARES name, the logo and STAR are trademarks of Heptares Therapeutics Ltd
Ylanthia® is a registered trademark of MorphoSys AG
SOURCE Heptares Therapeutics